ME02335B - Activin-actrii antagonisti i upotreba za liječenje anemije - Google Patents
Activin-actrii antagonisti i upotreba za liječenje anemijeInfo
- Publication number
- ME02335B ME02335B MEP-2016-200A MEP20016A ME02335B ME 02335 B ME02335 B ME 02335B ME P20016 A MEP20016 A ME P20016A ME 02335 B ME02335 B ME 02335B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- amino acid
- acid sequence
- use according
- antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims 14
- 208000007502 anemia Diseases 0.000 title claims 9
- 108010059616 Activins Proteins 0.000 title claims 5
- 102000005606 Activins Human genes 0.000 title claims 5
- 239000000488 activin Substances 0.000 title claims 5
- 102100021886 Activin receptor type-2A Human genes 0.000 title 1
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 3
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
Claims (17)
1. Aktivin-ActRII antagonist za upotrebu u lečenju ili prevenciji anemije kod humanog pacijenta kod koga postoji potreba za tim, naznačen time što je aktivin-ActRII antagonist – polipepid koji sadrži aminokiselinsku sekvencu izabranu iz grupe koju čine:a) aminokiselinska sekvenca SEQ ID NO: 2 ili aminokiselinska sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 2;b) aminokiselinska sekvenca SEQ ID NO: 3 ili aminokiselinska sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 3;c) polipeptid koji sadrži najmanje 50 uzastopnih aminokiselina izabranih iz SEQ ID NO: 2;d) aminokiselinska sekvenca SEQ ID NO: 16 ili aminokiselinska sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 16;e) aminokiselinska sekvenca SEQ ID NO: 17 ili aminokiselinska sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 17;f) polipeptid koji sadrži najmanje 50 uzastopnih aminokiselina izabranih iz SEQ ID NO: 16;g) aminokiselinska sekvenca SEQ ID NO: 7 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 7;h) aminokiselinska sekvenca SEQ ID NO: 12 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 12;i) aminokiselinska sekvenca SEQ ID NO: 20 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 20; ij) aminokiselinska sekvenca SEQ ID NO: 21 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 21.
2.Antagonist za upotrebu prema patentnom zahtevu 1, naznačen time što je navedeni polipeptid, aktivin-ActRII antagonist – fuzioni protein uključujući, pored navedenog polipeptida, aktivin-ActRII antagonista, jedan ili više polipeptidnih delova koji pojačavaju jedan ili više od in vivo stabilnosti, in vivo polu-života, unosa/primene, tkivne lokalizacije ili distribucije, formiranja proteinskih kompleksa i/ili prečišćavanja.
3. Antagonist za upotrebu prema patentnom zahtevu 2, naznačen time što navedeni fuzioni protein sadrži polipeptidni deo izabran iz grupe koju čine: imunoglobulinski Fc domen i serum albumin.
4. Antagonist za upotrebu prema bilo kom prethodnom patentnom zahtevu, naznačen time što navedeni aktivin ili ActRII antagonist polipeptid sadrži jedan ili više modifikovanih aminokiselinskih ostataka izabranih od: glikozilovane aminokiseline, PEGilovane aminokiseline, farnezilovane aminokiseline, acetilovane aminokiseline, biotinilovane aminokiseline, aminokiseline konjugovane za lipidnu grupu, i aminokiseline konjugovane za organsko derivatizujuće sredstvo.
5. Antagonist za upotrebu prema bilo kom prethodnom patentnom zahtevu, naznačen time što je anemija – anemija povezana sa multiplim mijelomom.
6.Antagonist za upotrebu prema bilo kom od patentnih zahteva 1 do 4, naznačen time što anemija povezana sa hroničnom bubrežnom bolešću kod pacijenta.
7. Antagonist za upotrebu prema bilo kom od patentnih zahteva 1 do 4, naznačen time što je anemija povezana sa hemoterapeutskim tretmanom pacijenta.
8.Antagonist za upotrebu prema bilo kom od patentnih zahteva 1 do 4, naznačen time što je anemija povezana sa mijelodisplastičnim sindromom.
9.Antagonist za upotrebu prema bilo kom od patentnih zahteva 1 do 4, naznačen time što je anemija povezana sa talasemijom.
10.Postupak za identifikaciju sredstva koji povećava nivoe eritrocita, naznačen time što taj postupak sadrži: a) dovođenje u kontakt sredstva od interesta sa izolovanim ActRII polipeptidom koji je obično sposoban da se vezuje za aktivin; b) dodavanje kompozicije koja sadrži aktivin; c) kvantitativno određivanje efikasnosti sredstva u inhibiciji formiranja kompleksa između ActII polipeptida i aktivina; i d) procenu efekta sredstva na nivoe eritrocita u životinji.
11.ActRII-Fc fuzioni protein za upotrebu u lečenju ili prevenciji anemije kod humanog pacijenta kod koga postoji potreba za tim, pri čemu ActRII-Fc fuzioni protein sadrži aminokiselinsku sekvencu koja je izabrana iz grupe koju čine: a) aminokiselinska sekvenca SEQ ID NO: 3 ili sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 3, b) aminokiselinska sekvenca SEQ ID NO: 2 ili sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 2, c) aminokiselinska sekvenca SEQ ID NO:7 ili sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 7, d) aminokiselinska sekvenca SEQ ID NO: 12 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 12; e) aminokiselinska sekvenca SEQ ID NO: 17 ili sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 17, e) aminokiselinska sekvenca SEQ ID NO: 16 ili sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 16, f) aminokiselinska sekvenca SEQ ID NO:20 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 20, i g) aminokiselinska sekvenca SEQ ID NO:21 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 21.
12.Protein za upotrebu prema patentnom zahtevu 11, naznačen time što izaziva manje od 15% povećanje u masi skeletnih mišića pacijenta.
13.Protein za upotrebu prema patentnom zahtevu 11 ili patentnom zahtevu 12, naznačen time što je primenjen tako da se dostigne koncentracija u serumu pacijenta od najmanje 100 ng/ml tokom perioda od oko 20 do 30 dana.
14.Protein za upotrebu prema bilo kom od patentnih zahteva 11 do 13, naznačen time što je primenjen tako da se dostigne koncentracija u serumu pacijenta u opsegu od 100 ng/ml do 1000 ng/ml.
15.Protein za upotrebu prema bilo kom od patentnih zahteva 11 do 14, naznačen time što ima polu-život u serumu od između 15 i 30 dana.
16.Protein za upotrebu prema bilo kom od patentnih zahteva 11 do 15, naznačen time što je za primenu na pacijenta ne češće od jednom nedeljno.
17.Protein za upotrebu prema patentnom zahtevu 16, naznačen time što je za upotrebu na pacijenta ne češće od jednom mesečno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87568206P | 2006-12-18 | 2006-12-18 | |
| PCT/US2007/025868 WO2008076437A2 (en) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonists and uses for increasing red blood cell levels |
| EP07863068A EP2124999B1 (en) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonists and uses for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02335B true ME02335B (me) | 2013-04-30 |
Family
ID=39183159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-200A ME02335B (me) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonisti i upotreba za liječenje anemije |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US7988973B2 (me) |
| EP (6) | EP2124999B1 (me) |
| JP (8) | JP5415279B2 (me) |
| KR (6) | KR101803620B1 (me) |
| CN (4) | CN104524548A (me) |
| AU (1) | AU2007334333B2 (me) |
| BR (1) | BRPI0720476B1 (me) |
| CA (1) | CA2672758C (me) |
| CO (1) | CO6230995A2 (me) |
| CR (1) | CR10889A (me) |
| DK (2) | DK2124999T3 (me) |
| EA (3) | EA035911B1 (me) |
| EC (1) | ECSP099514A (me) |
| ES (1) | ES2396734T3 (me) |
| HK (2) | HK1209624A1 (me) |
| HR (1) | HRP20121035T1 (me) |
| IL (5) | IL199451A (me) |
| ME (1) | ME02335B (me) |
| MX (2) | MX2009006651A (me) |
| MY (3) | MY188973A (me) |
| NZ (4) | NZ707292A (me) |
| PH (1) | PH12013500310B1 (me) |
| PL (2) | PL2124999T3 (me) |
| PT (1) | PT2124999E (me) |
| RS (1) | RS52537B (me) |
| SG (1) | SG10201702157QA (me) |
| SI (1) | SI2124999T1 (me) |
| UA (2) | UA116871C2 (me) |
| WO (1) | WO2008076437A2 (me) |
| ZA (2) | ZA200904454B (me) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
| USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| ES2561048T3 (es) * | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US9526759B2 (en) * | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8466187B2 (en) | 2007-09-18 | 2013-06-18 | Thermolife International, Llc | Amino acid compositions |
| KR101871510B1 (ko) | 2008-06-26 | 2018-06-26 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| CN107252486B (zh) * | 2008-06-26 | 2021-10-22 | 阿塞勒隆制药公司 | 激活素-actrii的拮抗剂及在提高红细胞水平中的用途 |
| LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| AU2015202035B2 (en) * | 2008-08-14 | 2017-03-23 | Acceleron Pharma Inc. | Use of GDF traps to increase red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010045518A1 (en) * | 2008-10-16 | 2010-04-22 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
| KR20170105124A (ko) | 2008-11-26 | 2017-09-18 | 암젠 인크 | 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도 |
| CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| CA2770822C (en) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| ES2613523T3 (es) * | 2009-09-09 | 2017-05-24 | Acceleron Pharma, Inc. | Antagonistas de ActRIIb y dosificación y usos de los mismos |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| US20110129469A1 (en) * | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| CN106795224B (zh) | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | 用促滤泡素抑制素多肽治疗病症的方法和组合物 |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3212213B1 (en) | 2014-10-30 | 2021-04-28 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| DK3227675T3 (da) * | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| WO2016123454A1 (en) * | 2015-01-29 | 2016-08-04 | Board Of Trustees Of Miching State University | Cryptic polypeptides and uses thereof |
| WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| WO2016154601A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| HK1250373A1 (zh) * | 2015-04-06 | 2018-12-14 | Acceleron Pharma Inc. | Alk7:actriib异多聚体和其用途 |
| DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| WO2016183280A1 (en) * | 2015-05-13 | 2016-11-17 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| WO2017006894A1 (ja) * | 2015-07-06 | 2017-01-12 | 三菱瓦斯化学株式会社 | 樹脂組成物、プリプレグ、レジンシート、積層板、及びプリント配線板 |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| RU2748278C2 (ru) | 2016-07-15 | 2021-05-21 | Акселерон Фарма Инк. | Композиции и способы лечения легочной гипертензии |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| JP6944768B2 (ja) | 2016-08-29 | 2021-10-06 | エア・ウォーター株式会社 | ペリクルの製造方法 |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN110461359B (zh) | 2017-03-24 | 2025-01-21 | 诺华股份有限公司 | 用于预防和治疗心脏病的方法 |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| PH12022551299A1 (en) | 2019-11-29 | 2023-11-20 | Kymab Ltd | Treatment for physiological iron overload |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| IL315206A (en) | 2021-02-11 | 2024-10-01 | Thermolife Int Llc | A method of administering nitric oxide gas |
| CA3226249A1 (en) * | 2021-08-16 | 2023-02-23 | Thermolife International, Llc | Iron supplement compositions and methods of use thereof |
| AU2023210700A1 (en) | 2022-01-28 | 2024-08-15 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| PE20260259A1 (es) * | 2023-03-09 | 2026-01-30 | Merck Sharp And Dohme Llc | Formulaciones que comprenden variantes polipeptidicas de actriia |
| EP4653010A1 (en) | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
| WO2025250605A1 (en) * | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US71927A (en) * | 1867-12-10 | Improvement in apparatus fob turning on gas | ||
| JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| WO1992004913A1 (en) * | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| AU654724B2 (en) | 1991-05-10 | 1994-11-17 | Salk Institute For Biological Studies, The | Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| JPH09503673A (ja) | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| ATE352638T1 (de) | 1995-04-11 | 2007-02-15 | Gen Hospital Corp | REVERSE ßTWO-HYBRIDß-SYSTEME |
| US6132988A (en) | 1995-10-27 | 2000-10-17 | Takeda Chemical Industries, Ltd. | DNA encoding a neuronal cell-specific receptor protein |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| EP1147413B1 (en) | 1999-01-21 | 2006-04-05 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| CA2365449A1 (en) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibitor of the growth of androgen-independent tumor |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| DE60026592T2 (de) * | 1999-12-15 | 2006-12-14 | Research Development Foundation, Carson City | Betaglycan als ein inhibin rezeptor und dessen verwendung |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| AU2002236558A1 (en) | 2000-12-01 | 2002-06-11 | Regents Of The University Of California | Method and composition for modulating bone growth |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US7074901B2 (en) | 2001-05-25 | 2006-07-11 | Serono Genetics Institute S.A. | Isolated human vCOL16A1 polypeptide and fragments thereof |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| JP2004121008A (ja) * | 2002-09-30 | 2004-04-22 | Toray Ind Inc | ネコアクチビンａおよびそのサブユニット並びにその製造法 |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2004086953A2 (en) | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005009460A2 (en) * | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| EP1732589A2 (en) | 2004-03-26 | 2006-12-20 | Acceleron Pharma Inc. | Bmp-3 propeptides and related methods |
| JP2008500816A (ja) | 2004-03-31 | 2008-01-17 | ゼンコー・インコーポレイテッド | 改善された性質を有するｂｍｐ−７変異体 |
| AU2005258286A1 (en) | 2004-06-24 | 2006-01-05 | Acceleron Pharma Inc. | GDF3 propeptides and related methods |
| ES2561048T3 (es) * | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| CA2581896C (en) | 2004-09-29 | 2015-11-10 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP1858541B1 (en) | 2005-02-16 | 2012-07-25 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency |
| EP1884235A1 (en) * | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Myeloerythroid progenitor differentiation inducer |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| CA2632544C (en) | 2005-12-06 | 2014-09-23 | Amgen Inc. | Use of myostatin antagonist for treating the effects of hypogonadism |
| WO2007084976A2 (en) | 2006-01-20 | 2007-07-26 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
| WO2007133653A2 (en) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Methods for treating blood disorders |
| EP2484352B1 (en) | 2006-07-21 | 2014-07-09 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| CA2685306A1 (en) | 2007-06-01 | 2008-12-11 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| PE20090510A1 (es) | 2007-08-03 | 2009-05-22 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| JP2011523357A (ja) | 2008-05-06 | 2011-08-11 | ジョスリン ダイアビーティス センター インコーポレイテッド | 褐色脂肪細胞分化を誘導するための方法および組成物 |
-
2007
- 2007-12-18 CN CN201410670950.5A patent/CN104524548A/zh active Pending
- 2007-12-18 PL PL07863068T patent/PL2124999T3/pl unknown
- 2007-12-18 KR KR1020157013795A patent/KR101803620B1/ko active Active
- 2007-12-18 SG SG10201702157QA patent/SG10201702157QA/en unknown
- 2007-12-18 KR KR1020217005960A patent/KR20210027508A/ko not_active Ceased
- 2007-12-18 CN CN201610144786.3A patent/CN105797135A/zh active Pending
- 2007-12-18 MY MYPI2016001928A patent/MY188973A/en unknown
- 2007-12-18 EA EA201201199A patent/EA035911B1/ru not_active IP Right Cessation
- 2007-12-18 EP EP07863068A patent/EP2124999B1/en active Active
- 2007-12-18 CA CA2672758A patent/CA2672758C/en active Active
- 2007-12-18 AU AU2007334333A patent/AU2007334333B2/en active Active
- 2007-12-18 US US12/002,872 patent/US7988973B2/en active Active
- 2007-12-18 SI SI200731110T patent/SI2124999T1/sl unknown
- 2007-12-18 CN CN201610145040.4A patent/CN105582521A/zh active Pending
- 2007-12-18 KR KR1020207006948A patent/KR102223231B1/ko active Active
- 2007-12-18 EP EP11195282A patent/EP2446896A1/en not_active Withdrawn
- 2007-12-18 NZ NZ707292A patent/NZ707292A/en unknown
- 2007-12-18 JP JP2009542880A patent/JP5415279B2/ja active Active
- 2007-12-18 EA EA200970603A patent/EA018037B1/ru unknown
- 2007-12-18 ME MEP-2016-200A patent/ME02335B/me unknown
- 2007-12-18 PL PL11195130T patent/PL2468290T3/pl unknown
- 2007-12-18 NZ NZ720955A patent/NZ720955A/en unknown
- 2007-12-18 MX MX2009006651A patent/MX2009006651A/es active IP Right Grant
- 2007-12-18 EP EP17182870.0A patent/EP3320911B1/en active Active
- 2007-12-18 EP EP21205033.0A patent/EP4026553A1/en not_active Withdrawn
- 2007-12-18 BR BRPI0720476-0A patent/BRPI0720476B1/pt active IP Right Grant
- 2007-12-18 PH PH1/2013/500310A patent/PH12013500310B1/en unknown
- 2007-12-18 MY MYPI20092540A patent/MY162136A/en unknown
- 2007-12-18 NZ NZ617196A patent/NZ617196A/en unknown
- 2007-12-18 UA UAA201214689A patent/UA116871C2/uk unknown
- 2007-12-18 UA UAA200906746A patent/UA101309C2/ru unknown
- 2007-12-18 MY MYPI2013002844A patent/MY170509A/en unknown
- 2007-12-18 EP EP11195140.6A patent/EP2468291B1/en active Active
- 2007-12-18 PT PT78630688T patent/PT2124999E/pt unknown
- 2007-12-18 HR HRP20121035TT patent/HRP20121035T1/hr unknown
- 2007-12-18 KR KR1020167001731A patent/KR101831534B1/ko active Active
- 2007-12-18 RS RS20120548A patent/RS52537B/sr unknown
- 2007-12-18 KR KR1020097014226A patent/KR101688228B1/ko active Active
- 2007-12-18 DK DK07863068.8T patent/DK2124999T3/da active
- 2007-12-18 EA EA202091230A patent/EA202091230A3/ru unknown
- 2007-12-18 KR KR1020187004410A patent/KR20180019768A/ko not_active Ceased
- 2007-12-18 WO PCT/US2007/025868 patent/WO2008076437A2/en not_active Ceased
- 2007-12-18 NZ NZ577847A patent/NZ577847A/en unknown
- 2007-12-18 DK DK11195130.7T patent/DK2468290T3/en active
- 2007-12-18 EP EP11195130.7A patent/EP2468290B1/en active Active
- 2007-12-18 ES ES07863068T patent/ES2396734T3/es active Active
- 2007-12-18 MX MX2012002498A patent/MX373050B/es unknown
- 2007-12-19 CN CN200780051416.4A patent/CN101687015B/zh active Active
-
2008
- 2008-09-29 US US12/286,333 patent/US8007809B2/en active Active
- 2008-09-29 US US12/286,381 patent/US20100204092A1/en not_active Abandoned
-
2009
- 2009-06-18 IL IL199451A patent/IL199451A/en active IP Right Grant
- 2009-06-24 CR CR10889A patent/CR10889A/es unknown
- 2009-06-25 ZA ZA2009/04454A patent/ZA200904454B/en unknown
- 2009-07-09 CO CO09071017A patent/CO6230995A2/es not_active Application Discontinuation
- 2009-07-14 EC EC2009009514A patent/ECSP099514A/es unknown
-
2011
- 2011-07-22 US US13/189,353 patent/US20120052067A1/en not_active Abandoned
-
2012
- 2012-03-19 ZA ZA2012/02027A patent/ZA201202027B/en unknown
-
2013
- 2013-03-18 JP JP2013055102A patent/JP5865281B2/ja active Active
- 2013-11-26 JP JP2013243668A patent/JP2014040483A/ja active Pending
-
2015
- 2015-08-12 IL IL240523A patent/IL240523A/en active IP Right Grant
- 2015-08-12 IL IL240524A patent/IL240524A/en active IP Right Grant
- 2015-10-22 HK HK15110382.8A patent/HK1209624A1/xx unknown
- 2015-10-27 JP JP2015211115A patent/JP2016020391A/ja active Pending
-
2017
- 2017-02-03 JP JP2017018409A patent/JP2017075187A/ja active Pending
- 2017-06-19 JP JP2017119494A patent/JP2017155064A/ja not_active Withdrawn
- 2017-12-11 IL IL256247A patent/IL256247B/en unknown
-
2018
- 2018-10-31 HK HK18113934.2A patent/HK1254840A1/en unknown
-
2019
- 2019-01-04 US US16/240,276 patent/US20200031903A1/en not_active Abandoned
- 2019-03-12 JP JP2019044553A patent/JP2019089850A/ja not_active Withdrawn
-
2020
- 2020-12-23 US US17/132,024 patent/US20210355191A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021032007A patent/JP2021080290A/ja active Pending
- 2021-07-07 IL IL284693A patent/IL284693A/en unknown
- 2021-08-05 US US17/395,365 patent/US20220204588A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02335B (me) | Activin-actrii antagonisti i upotreba za liječenje anemije | |
| HRP20191109T1 (hr) | Gdf klopke za uporabu u liječenju anemije | |
| JP2010513506A5 (me) | ||
| HRP20120947T1 (hr) | FARMACEUTSKE SMJESE KOJE SADRŽE AKTIVIN-ActRIIA ANTAGONISTE I NJIHOVA UPORABA U PREVENCIJI ILI LIJEÄŚENJU MULTIPLOG MIJELOMA | |
| JP2013127002A5 (me) | ||
| WO2004066932A3 (en) | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | |
| EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
| Clark et al. | Species differences in Cl− affinity and in electrogenicity of SLC26A6‐mediated oxalate/Cl− exchange correlate with the distinct human and mouse susceptibilities to nephrolithiasis | |
| ATE454124T1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| Nakaya et al. | Amino acid sequence and disulfide bridges of an antifungal protein isolated from Aspergillus giganteus | |
| JP2011530599A5 (me) | ||
| JP2010518006A5 (me) | ||
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| RS58726B1 (sr) | Kompozicije insulina sa brzim dejstvom | |
| RS62633B1 (sr) | Analozi hepcidina i njihove primene | |
| WO2004019878A3 (en) | Adzymes and uses thereof | |
| EP3145530B1 (en) | Trail receptor agonists for treatment of fibrotic diseases | |
| AU2012205384A1 (en) | IL-27 antagonists for treating inflammatory diseases | |
| Lima et al. | Identification of E. dysenterica laxative peptide: A novel strategy in the treatment of chronic constipation and irritable bowel syndrome | |
| JP2004535461A5 (me) | ||
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| KR20200138254A (ko) | C-말단 항체 변이체 | |
| Harada et al. | Activated neutrophils impair gastric cytoprotection: role of neutrophil elastase | |
| WO2008117730A1 (ja) | 肝疾患の予防または治療用組成物 | |
| DE102021005922A1 (de) | Inhibierung der Interaktion zwischen viralen Spike Proteinen von SARS-CoV-2 und dem humanen Angiotensin-konvertierenden Enzym 2 (hACE2) |